{"name":"Christopher O'Brien, MD","slug":"christopher-o-brien-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPWmhfNHNZdVo4VTZhMHBTMmdzYVdSMGZVSm9oejRSS2o1blJQSkhHS1pyVmFDdXlBSzlkNXJxalVDMEo2ZUNIZ0VWaHRRaGZqSmN2djZTYjRxQ0NtRHV2bzM5UW9QcTFzV0ZXQ1ZBNlpXWS11cjF3M0U2SElyb3dlaHJIbWx5eE04OVN3eDJ0bkNaVWg3ckpwMmR3azhYYmZHdEVWZ3c4VVhnVU84c3pocnJwM2hMSnVhUURXdw?oc=5","date":"2026-03-12","type":"pipeline","source":"Stock Titan","summary":"Ex-Australian Army officer to lead Infleqtion’s quantum defense push - Stock Titan","headline":"Ex-Australian Army officer to lead Infleqtion’s quantum defense push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPZmdCUkY3MWJRYUQxdktxY2RKSUd0S0pheGxPLUNBRTdyX3J0czlmMnZ6aDQxZE9sY2RVWWdtWXFuc0pwRzktZ213QUVVWjk5MHlVMTR4VVV5QTkxelREdmdUYWdGamR1amxoOUFpRXdhMVhkTkJCYkcyOVFvQmFNY3ZlbHFxMVZoeGtLSEZVcng2eTFDU0RWUkNKUGpJSDZON3laYXRzV200THNKT3JjSg?oc=5","date":"2025-07-21","type":"pipeline","source":"forbes.com.au","summary":"Why investors have put $100m behind Australian biotech’s ‘Trojan horse’ for cancer - forbes.com.au","headline":"Why investors have put $100m behind Australian biotech’s ‘Trojan horse’ for cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNeml0cGpyaG9DZFBaT2thVTVnUFhEVGpaOEY5WTMxU0JaUVhGODlMb2E0Rkk3VXNabGstOGNxRHM2V25tX0o5cTV0UFdSVmt0azhpR1lvWlRwUlh6VGJ5ZXI1cmxfMUFtcmp0LWFva0haTi0tRl80SGVRS0xNZHIwaUV3?oc=5","date":"2025-07-17","type":"pipeline","source":"Medical Marketing and Media","summary":"The Escalator: Johnson & Johnson MedTech, Jazz Pharmaceuticals, Kenvue and more - Medical Marketing and Media","headline":"The Escalator: Johnson & Johnson MedTech, Jazz Pharmaceuticals, Kenvue and more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxOd0VXd040bXhnZ2xIUWxMa2Nva0dGLXc5NWRsU3Q4MzRSamdXN2xzOXMycEhUMTR4MGt6TXVHVFpPekhYQTlKYlp2U095dENzWlBoNHdQQ2VpaXZUQ2NLMzJ5YjRDbExWSkMwcTBSMzJ6NjVOYnUtRFBRLWtzMWtXMFh1X0dMMVBXT2Y1OFgzR21EM1JyS3dsSnkwRHdqOXFwcXFUbEtRcFVPeTI4dWV3ZDhNOTF0cThiejNkOHFuRGlBRkgwMVVNMWNYb2hBeTV0dGRNdnNtclVQZl9sazBDckZGdmtqY1d6?oc=5","date":"2025-01-29","type":"regulatory","source":"respiratory-therapy.com","summary":"FDA Accepts New Drug Application for Inhaled Dry Powder Asthma Therapy - respiratory-therapy.com","headline":"FDA Accepts New Drug Application for Inhaled Dry Powder Asthma Therapy - respiratory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOT2xwY1BucFVYTTI3UktFVTcyVTRNVEtZMi1PVUo0UjdHLWtsbmRQV0g3MkRBRVlFQ3h6Y0dub2xkV0JmQzNfcXluTHQtVW5LOXZIRVdkUVlXQ05jV1FZRU5sWURNSHNpc0F3Z19DMkJaNDIxOTZoYXJPcjloNEYzLTMtUWo5Zk5OQ2hNUExvN05PWVNZU240dnhzaktLUEppQjUwYUp0WVp1UkxqR0lZQ2wxaDVtd3V3MVUyS0IzMFhaejNRRV81YVZoWFpaVTVnX1dvQW1Kamk0OS1kdGN2WHU1VmtST2MwemRRTFpvTWVwQUxDMFpV?oc=5","date":"2025-01-29","type":"regulatory","source":"Business Wire","summary":"Kinaset Therapeutics Announces FDA Clearance of IND Application for frevecitinib (KN-002) in Asthma Treatment - Business Wire","headline":"Kinaset Therapeutics Announces FDA Clearance of IND Application for frevecitinib (KN-002) in Asthma Treatment","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-09-04","type":"trial","source":"Business Wire","summary":"Kinaset Therapeutics to Share Outcomes from the Phase 1 Clinical Evaluation of Frevecitinib (KN-002), an Inhaled Pan JAK Inhibitor, in Patients with Moderate to Severe Asthma and COPD via Oral Present","headline":"Kinaset Therapeutics to Share Outcomes from the Phase 1 Clinical Evaluation of Frevecitinib (KN-002), an Inhaled Pan JAK","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQcllhOHlGaHFVOEpXVUJERzRmUkZ1WDE5QjgtOG5pWlg5QWQ1VVhVcTNFMGZtV2I1cm8yd0g1cFluMHQtdDNjNEdKQzg0d3ZFZkEwSW5KaURCNHlHWTRETUZGOWYzRTZOMjM0U2Q3MjFYVXhidHQ3ejh0azhIbUtuNmsxUnJ5czU0ZERNTHkwcWsxMTI4eXlCM1dBdXdMdw?oc=5","date":"2024-05-29","type":"pipeline","source":"Legacy","summary":"Kevin O’Brien Obituary (2024) - Las Vegas, NV - San Diego Union-Tribune - Legacy","headline":"Kevin O’Brien Obituary (2024) - Las Vegas, NV - San Diego Union-Tribune","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOczUyVFpjQmhXQW5uYXNJMGFCQTlnZ0d1TEotRm8wN2FaR2tqcWhDNTVIYjlkbURrVUxMb0lReksxb0pReS1VajkwWmRYZ2xGT1lqNlNvbjdSQ2ViQnVNbHRJMndzSjF6cEhKdDJJODFyc3Fkdk15TEJYOXRnSlRMYzZ3UEtYOVVxaGd5MDlHQVBFMTZ2XzBlaWNQLThmOV9qSTBhSXF6ZGZhV3RHMVJRbDJKUFF4M1FQ?oc=5","date":"2023-01-26","type":"pipeline","source":"Healio","summary":"Season of birth may be associated with risk for adult-onset asthma - Healio","headline":"Season of birth may be associated with risk for adult-onset asthma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxObld0X3JJc3VoVkx0cy1fRnFudGF2ZnBqMUxOQlZaN2N2cTl6WVFtdWFNYWYteTVxNHgyTF9PME54a1A1Y01hX2sxbE0tUVpGZjVZLXhxWW5KY0N3dlk0U3JJV0l4X3JBS3ROV2NDODJhMWZNV0xnSmNYZjhKcHgzRWMzTURpXzlkX1Y1cA?oc=5","date":"2021-09-29","type":"pipeline","source":"Legacy","summary":"Christopher Brown Obituary (2021) - 73, Spring Lake Heights, NJ - Asbury Park Press - Legacy","headline":"Christopher Brown Obituary (2021) - 73, Spring Lake Heights, NJ - Asbury Park Press","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE53eU0yQVd5MTdkN19kYnhudDJYcHp4QmVIaWI5TWNXWXQxd3Y2c00xVUtZLW1hZ2lsMzZRMnhrSkZsUEVJeW5YLWNLNExDbzhYYlp5REIyVkZDdG5ZODNJSw?oc=5","date":"2019-09-25","type":"pipeline","source":"NEJM","summary":"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis - NEJM","headline":"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNUFRXUktPalF0Y1FLMjNlSzN5TzYxUjVFbG5NZmpsbzdlZnE3TTBBU08yblplb2diMGFLSDNoamNXTHpMZ0xhaDhMMlA1SXlEM05BUXpyRUtMR2gtUS1SbDIyTU9TamlRLXlTV1k0eVJabF9xVng5aUJkLV8zMXpNdUFxS1BjMmdWTF9NY2F2clczQURTT3BiT3NOMU11VFUzZTFXaTUtTmJUVmRv?oc=5","date":"2018-01-12","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Pfizer oncology head Liz Barrett jumps ship to Novartis - Fierce Biotech","headline":"Chutes & Ladders—Pfizer oncology head Liz Barrett jumps ship to Novartis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTFBMOTRBZ1I3M3NNVjJESHRXVDBiMWQ1UHA3Wkg2emUtMXJQX3VGUG05Y3VoMXAtYVlPRnpzYzZNTlZTbGdwd2tYN2xONzVBLTh2TVdiVTBlRmFIZzh6aWstbVNQTDJXbGd6WUpKaUpnNjA?oc=5","date":"2017-03-21","type":"trial","source":"Psychiatry Online","summary":"KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia - Psychiatry Online","headline":"KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}